# Jennifer Bergheiser

> Jennifer Bergheiser is the Chief Business Officer of eGenesis, the Cambridge biotech turning gene-edited pig organs into a real answer to the transplant waitlist. She runs corporate strategy and all portfolio and commercial development, drawing on more than two decades across big pharma, venture capital, and consulting. Her resume runs from screening deals at Domain Associates to steering the blockbuster autoimmune drug Stelara at Centocor/Johnson & Johnson. At eGenesis she helps commercialize one of medicine's boldest bets: organs grown in pigs, edited dozens of times over, transplanted into living humans.

- **Role:** Chief Business Officer at eGenesis
- **Organizations:** eGenesis, hatch health, Genactis, Centocor / Johnson & Johnson, Acureon Pharmaceuticals, Domain Associates, Accenture
- **Nationality:** American
- **Education:** MBA, The Wharton School, University of Pennsylvania, B.A. in Economics and History, University of Pennsylvania
- **Known for:** Leads corporate strategy and all portfolio and commercial development at eGenesis., Brings 20+ years of biopharmaceutical experience across big pharma, small biotech, venture investing, and consulting., Helped steer pre-launch and lifecycle work for Stelara, a blockbuster autoimmune therapy, at Centocor/Johnson & Johnson.

## Career timeline

- **Early career** — Began in management consulting within Accenture's Pharmaceutical and Medical Products Strategy practice, supporting large pharma on product launch, organizational design, and pricing and market access.
- **Venture** — Joined Domain Associates in venture capital, screening and evaluating new investments and supporting portfolio companies including ESP Pharma, Peninsula Pharmaceuticals, and Proxima Therapeutics; served as board observer at TargetRx and Proxima.
- **Operating** — Led strategy and business development at Acureon Pharmaceuticals, a venture-backed anti-infectives startup.
- **Operating** — At Centocor/Johnson & Johnson, oversaw commercial product development, market development, and lifecycle management for blockbuster injectable Stelara and other autoimmune biologics.
- **Consulting** — Served as Managing Director at Genactis, leading biotech clients on new product and portfolio planning and business development.
- **Consulting** — Served as Managing Principal at hatch health, consulting private and public life science companies on new product planning, corporate strategy, business development, and due diligence.
- **Present** — Chief Business Officer at eGenesis, leading corporate strategy and all portfolio and commercial development.

## Achievements

- Leads corporate strategy and all portfolio and commercial development at eGenesis.
- Brings 20+ years of biopharmaceutical experience across big pharma, small biotech, venture investing, and consulting.
- Helped steer pre-launch and lifecycle work for Stelara, a blockbuster autoimmune therapy, at Centocor/Johnson & Johnson.
- Supported VC investments at Domain Associates that resulted in liquidity events.

## Latest updates

- **2024-03** — eGenesis's gene-edited pig kidney was transplanted into a living patient at Massachusetts General Hospital, a landmark in xenotransplantation.
- **2024-09** — eGenesis raised a Series D round; the company has raised roughly $481M in total funding.
- **2024-12** — eGenesis received FDA clearance to extend its approach into a multi-patient clinical trial.

## Links

- Website: https://egenesisbio.com
- LinkedIn: http://www.linkedin.com/in/jennifer-bergheiser-8310b65

---

Profile page: https://yespress.io/jennifer-bergheiser
Published by YesPress — https://yespress.io
Last updated: 2026-06-11